Home › Funds › Partners Group Holding AG › RPRX

Partners Group Holding AG position in RPRX

ROYALTY PHARMA PLC · Health Care

Partners Group Holding AG reported holding 214,451 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$12.5M, representing 1.22% of its reported portfolio and ranking #26 among its reported holdings. Partners Group Holding AG has disclosed RPRX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)214.45K sh
Reported value held$12.52M
Portfolio Weight1.22%
First reportedQ4 2025
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Partners Group Holding AG's RPRX position evolved

Partners Group Holding AG first disclosed a stake in RPRX in Q4 2025 at 49,855 shares (US$1.9M). The position peaked in Q3 2026 at 214,451 shares, worth US$12.5M. Across 4 filings, Partners Group Holding AG increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 214,451 shares valued at US$12.5M — an increase of 56,507 shares quarter over quarter.. Notable position changes include a 75% increase in Q1 2026 (shares rose 17% over the following quarter), a 81% increase in Q2 2026 (shares rose 4% over the following quarter), a 36% increase in Q3 2026 (shares rose 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 49.85K $1.93M New
Q1 2026 87.06K $4.18M Add
Q2 2026 157.94K $8.86M Add
Q3 2026 214.45K $12.52M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RPRX and 13F data

RPRX (ROYALTY PHARMA PLC) is a Health Care company. 48 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RPRX

All RPRX fund holders →

FAQ

How long has Partners Group Holding AG held RPRX?

Partners Group Holding AG has disclosed RPRX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Partners Group Holding AG's current position in RPRX?

As of Q3 2026, Partners Group Holding AG holds 214.45K shares of RPRX (ROYALTY PHARMA PLC), valued at $12.52M, representing 1.22% of its reported portfolio and ranking #26.

Has Partners Group Holding AG been buying or selling RPRX?

In the latest 13F filing (Q3 2026), Partners Group Holding AG increased its position in RPRX. The position peaked in Q3 2026 at 214.45K shares.

Which other funds hold RPRX?

Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, ROYAL LONDON ASSET MANAGEMENT LTD, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.